|
Emerging Markets Encouraged to Focus on Most Likely Counterfeits
Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered U.S. Food and Drug Administration (FDA)-approved products before testing for quality issues, according to a new study. Given the high quality of drugs approved by stringent regulatory authorities like the FDA, this approach would help focus attention on prior testing of drugs more likely to be substandard or counterfeit, according to the working paper published recently by the National Bureau of Economic Research.
International Pharmaceutical Regulatory Monitor |
Register Now
Archives